Trials
5 active
5 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “JSB462 is administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.”In the company’s words, NCT06991556 on ClinicalTrials.gov
- Tested for
- Metastatic Hormone-sensitive Prostate Cancer, Prostatic Cancer, Castration-Resistant, Prostate Cancer Metastatic, Progressive Metastatic Castrate Resistant Prostate Cancer, Metastatic Prostate Cancer (mCRPC)
- Main trialPhase 2
- “This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated”In the company’s words, NCT06991556 on ClinicalTrials.gov
- Other names
- luxdegalutamide · ARV-766
Other drugs for Metastatic Hormone-sensitive Prostate Cancer
- PembrolizumabMerck & Co. · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Intismeran autogeneMerck & Co. · Moderna · Phase 3
- LenvatinibMerck & Co. · Eisai · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- CalderasibMerck & Co. · Phase 3
Coming up5
- 3 DecPhase 2 trial completes · ClinicalTrials.gov
- 29 Jan 2027Phase 1 trial completes · ClinicalTrials.gov
- 25 May 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 16 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 9 Nov 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovCompletion date moved: 2032-03-15 to 2026-12-03 · ClinicalTrials.gov NCT06991556
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 3 Dec 2026 | An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | |
| Phase 2Active, not recruiting | 16 Jul 2027 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | |
| Phase 1/2Active, not recruiting | 25 May 2027 | A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | |
| Phase 1/2Recruiting | 9 Nov 2029 | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | |
| Phase 1Active, not recruiting | 29 Jan 2027 | A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026